Selected adverse events during the 12-week induction period of a phase III trial of vunakizumab: an exploratory post-hoc analysis.

What was studied

This post-hoc analysis looked at adverse events with vunakizumab. The aim was to see what the drug adds to adverse events. Patients had moderate-to-severe plaque psoriasis. Data came from a late-stage trial over a 12-week induction period. 690 patients were included. The main outcome was any adverse event during the 12 weeks.

What they found

Many patients had an adverse event. The rate did not differ significantly between the groups. Vunakizumab was not an independent factor for any adverse event. Skin and subcutaneous diseases were less frequent with vunakizumab than with placebo. Injection site reaction was more frequent with it. After excluding psoriasis flares, the skin link was no longer significant.

What it means for patients

The authors say vunakizumab is not significantly tied to any adverse event. It is also not tied to most event groups. It is tied to more injection site reactions and fewer skin and tissue diseases. They say the lower skin rate may reflect better psoriasis control. It may not be a specific safety gain.

Why it is not certain yet

This was an exploratory post-hoc analysis. The lower skin rate may reflect psoriasis control, not safety. The abstract names no other limits.

Source

Selected adverse events during the 12-week induction period of a phase III trial of vunakizumab: an exploratory post-hoc analysis.

We restate facts from the source record in our own words. The original wording belongs to its publisher.